Get the Stockscreener App
68.80
1.46%
0.87
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $68.80, with a volume of 463.87K.
It is up +1.46% in the last 24 hours and up +1.69% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$67.93
Open:
$68.04
24h Volume:
463.87K
Relative Volume:
0.24
Market Cap:
$33.57B
Revenue:
$10.63B
Net Income/Loss:
$819.00M
P/E Ratio:
41.50
EPS:
1.6577
Net Cash Flow:
$1.59B
1W Performance:
+6.56%
1M Performance:
+1.69%
6M Performance:
-14.03%
1Y Performance:
-21.29%
1-Day Range:
$67.91
$69.27
1-Week Range:
$64.90
$69.27
52-Week Range:
$61.84
$92.55
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
68.84 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
ISRG
Intuitive Surgical Inc
|
406.58 | 142.31B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.84 | 40.72B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
37.10 | 30.48B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
201.72 | 28.50B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Alcon, analysts point to a clear Buy consensus - Ad-hoc-news.de
Intraocular Lens Market to Witness Transformational Growth Opportunities by 2032 – DelveInsight | Johnson & Johnson, Alcon, Bausch & Lomb, ZEISS Group, STAAR Surgical, Hoya Corporation - Barchart.com
Alcon focuses on surgical and vision care strategy, shares trade steadily in SIX listing - Ad-hoc-news.de
Alcon highlights cataract surgery growth strategy, shares trade steadily in Swiss listing - AD HOC NEWS
The Systane Ultra Lubricant Eye Drops from Alcon Inc.everyday dry-eye relief in compact vials - Ad-hoc-news.de
Alcon refines long-term strategy, shares supported by clear analyst consensus - AD HOC NEWS
Alcon Inc. (ALC) Stock Analysis: Eyeing A 35.93% Upside In The Healthcare Sector - DirectorsTalk Interviews
Quiet comfort in the eyewhy Alcon’s PRECISION1 daily lenses feel almost invisible - AD HOC NEWS
Alcon StockWeekly review and sector comparison - AD HOC NEWS
Soft start into silicone hydrogel, Alcon’s PRECISION1 daily lens aims for easy wearers - AD HOC NEWS
Why Alcon’s SYSTANE Hydration PF has become a quiet everyday essential - AD HOC NEWS
Alcon AG (ALC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
New contact lens comfort data puts Alcon’s DAILIES TOTAL1 center stage - AD HOC NEWS
Alcon launches Unity CS cataract surgery system in Canada - Investing.com UK
New treatment option for cataract surgeons, Alcon Clareon IOL expands premium lineup - AD HOC NEWS
BNY Mellon International Stock Fund's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
Canadian launch sets the stage for Alcon’s UNITY CS cataract system - AD HOC NEWS
Alcon Inc Stock (CH0432492467): Eye-care leader in focus after recent trading and sector moves - AD HOC NEWS
Alcon launches Unity CS cataract surgery system in Canada By Investing.com - Investing.com South Africa
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada - Eagle-Tribune
Alcon Inc. (ALC) Stock Analysis: Eyeing A 31.52% Potential Upside In The Healthcare Market - DirectorsTalk Interviews
Alcon Inc. Stock (CH0432492467): Ownership changes put the eye-care group in focus - AD HOC NEWS
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
Alcon Inc. Stock (CH0432492467): Valuation metrics keep eye-care leader in focus - AD HOC NEWS
Alcon Inc Stock (CH0432492467): Citi reiterates Buy rating and sees upside potential - AD HOC NEWS
Alcon DAILIES TOTAL1 contact lenses: daily comfort for dry-eye wearers - AD HOC NEWS
KeyBanc Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $88 - Moomoo
Alcon (ALC) Gets a Buy from Citi - The Globe and Mail
Citi Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $103 - Moomoo
Alcon Inc Stock (CH0432492467): Analyst targets highlight upside after Q1 update - AD HOC NEWS
Systane class action claims eye drops falsely advertised as preservative-free - Class Action Lawsuits
Alcon Inc. stock (CH0432492467): eye-care specialist steadies after Q1 2026 update - AD HOC NEWS
Alcon Inc stock (CH0432492467): eye-care specialist steadies after Q1 earnings and dividend update - AD HOC NEWS
Alcon Inc stock (CH0432492467): Eye-care specialist in focus after recent earnings and outlook - AD HOC NEWS
Alcon Inc. stock (CH0432492467): eye-care specialist edges higher after Q1 earnings and guidance upd - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Eye-care specialist builds on Q1 earnings momentum - AD HOC NEWS
Alcon Inc stock (CH0432492467): eye-care specialist in focus after recent earnings update - AD HOC NEWS
Alcon Inc. (ALC) Stock Analysis: Healthcare Giant With 32.5% Upside Potential - DirectorsTalk Interviews
BTIG lowers Alcon stock price target to $82 on lower valuation - Investing.com
Alcon faces class-action lawsuit over false product marketing - Eyes On Eyecare
Alcon shares see BofA reiterate underperform on soft Q1 results - Investing.com
Alcon Q1 2026 slides: EPS beats but revenue miss sparks selloff - Investing.com
Alcon Inc stock (CH0432492467): shares steady after Q1 2026 earnings beat and raised guidance - AD HOC NEWS
Swiss eye care firm Alcon's quarterly revenue rises less than expected - marketscreener.com
Is It Too Late to Buy Alcon Inc (ALC) After 3.7% Rally? GF Value Says Undervalued - GuruFocus
Alcon Inc stock (CH0432492467): sector backdrop in focus as shares consolidate - AD HOC NEWS
Alcon Inc. stock (CH0432492467): shares hover in mid-60 USD range on NYSE as investors await next ea - AD HOC NEWS
Alcon Inc. stock (CH0432492467): shares near mid-60 USD range ahead of next earnings update - AD HOC NEWS
Recalled Systane, GenTeal Tears Eye Products Falsely Labeled as ‘Sterile’ Despite Contamination Risks, Class Action Claims - ClassAction.org
Alcon Inc. (ALC) Stock Analysis: Eyeing a 33.54% Potential Upside in the Growing Healthcare Sector - DirectorsTalk Interviews
Alcon Inc stock (CH0432492467): Shares steady as investors digest Q1 2026 results and eye care marke - AD HOC NEWS
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):